Search research articles
Contact Us
Filters
Showing results (61-70 of 289) with videos related to
Page
of 29
Sort By:
British Journal of Cancer
|
August 1, 1996
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
H Anderson, N Thatcher, J Walling, et al.
Seminars in Oncology
|
June 1, 1994
Intensive combined-modality therapy in small cell lung cancer
N Thatcher, P Lorrigan, P Burt, et al.
Respiratory Medicine
|
May 1, 1990
DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival
H Dazzi, N Thatcher, P S Hasleton, et al.
Australian and New Zealand Journal of Medicine
|
October 1, 1982
Reversible renal failure due to renal cholesterol embolism
S W Ho, G N Thatcher, L R Matz
International Journal of Cancer
|
March 15, 1989
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2
A K Ghosh, H Dazzi, N Thatcher, et al.
British Journal of Cancer
|
March 1, 1990
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies
A K Ghosh, M Mellor, J Prendiville, et al.
British Journal of Cancer
|
April 1, 1986
Genetic predisposition to human lung cancer
J Heighway, N Thatcher, T Cerny, et al.
British Journal of Diseases of the Chest
|
April 1, 1983
A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent
K B Carroll, H Moussalli, D Brown, et al.
Biochemical Society Transactions
|
November 1, 1994
Magnetic resonance spectroscopy studies on Ca2+, Zn2+ and energy metabolism in superfused brain slices
H Bachelard, R Badar-Goffer, P Morris, et al.
Cancer Treatment Reviews
|
June 1, 1989
Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study
N Thatcher, H Dazzi, A Gosh, et al.
Page
of 29
Search research articles
Search
Showing results (61-70 of 289) with videos related to
Sort By:
Page
of 29
British Journal of Cancer
|
August 1, 1996
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
H Anderson, N Thatcher, J Walling, et al.
Seminars in Oncology
|
June 1, 1994
Intensive combined-modality therapy in small cell lung cancer
N Thatcher, P Lorrigan, P Burt, et al.
Respiratory Medicine
|
May 1, 1990
DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival
H Dazzi, N Thatcher, P S Hasleton, et al.
Australian and New Zealand Journal of Medicine
|
October 1, 1982
Reversible renal failure due to renal cholesterol embolism
S W Ho, G N Thatcher, L R Matz
International Journal of Cancer
|
March 15, 1989
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2
A K Ghosh, H Dazzi, N Thatcher, et al.
British Journal of Cancer
|
March 1, 1990
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies
A K Ghosh, M Mellor, J Prendiville, et al.
British Journal of Cancer
|
April 1, 1986
Genetic predisposition to human lung cancer
J Heighway, N Thatcher, T Cerny, et al.
British Journal of Diseases of the Chest
|
April 1, 1983
A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent
K B Carroll, H Moussalli, D Brown, et al.
Biochemical Society Transactions
|
November 1, 1994
Magnetic resonance spectroscopy studies on Ca2+, Zn2+ and energy metabolism in superfused brain slices
H Bachelard, R Badar-Goffer, P Morris, et al.
Cancer Treatment Reviews
|
June 1, 1989
Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study
N Thatcher, H Dazzi, A Gosh, et al.
Page
of 29